{
  "docId": "019de076-9434-73df-8e70-401e13bb3d65",
  "docSlug": "692690be0ea25b83b6a4c7490ff14999",
  "documentTitle": "BioAtla | Investor Presentation Deck | 55 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 55,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a three-column layout to compare different therapeutic modalities enabled by the same platform technology.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9434-73df-8e70-401e13bb3d65/7",
  "deckHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65",
  "deckJsonHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65.json",
  "deckAnchorHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.11,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "ADC - antibody drug conjugate; IO - immuno-oncology; TCE - T-cell engager",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed75a908-2f5e-452d-9688-e008bc00e664",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "image",
      "text": "Antibody diagrams for I/O, ADC, and Bispecific TCE",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24e189ce-2f86-4900-847b-843a312ef36e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.67,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "Bispecific TCE: Target: EpCAM & CD3. Bispecific antibodies bridge cancer cells and cytotoxic T lymphocytes, activating T cells and promoting cancer cell lysis.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4af5ec64-535b-4976-a717-f81affe338b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.05,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "I/O Antibodies: Target: CTLA-4. CTLA-4 blockade activates effector T cells, thereby enhancing anti-tumor immunity.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "986780be-735a-45af-a126-6bce26c988ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.36,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "ADCs: Targets: AXL, ROR2. Widely expressed in a variety of tumor types, AXL and ROR2 overexpression correlates with poor prognosis, metastasis, and drug resistance to PD-1 and EGFR therapies.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eeae5bf0-bed1-4df0-b069-4add84fa9d1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "has the potential to treat multiple solid tumors",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d19e1a61-a294-496f-8e93-10351469e4c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Broad applicability of BioAtla's CAB platform across several antibody types",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d2453dc-9c1e-4b27-ab5c-c7246bc30c4b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "6bd9196b-3c24-4ee3-929a-95224779d4db",
      "evidence": "The slide features a diagram comparing healthy cells and cancer cells with CAB binding in acidic environments, which can be interpreted as a 2x2 matrix.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}